


## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## **Single Technology Appraisal**

# Ibrutinib with R-CHOP for untreated mantle cell lymphoma when an autologous stem cell transplant is suitable ID6596

## **Provisional Stakeholder List**

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Janssen-Cilag (ibrutinib)	All Wales Therapeutics and Toxicology     Centre
Patient/carer groups	Allied Health Professionals Federation
<ul><li>African Caribbean Leukaemia Trust</li><li>Anthony Nolan</li></ul>	Board of Community Health Councils in Wales
Black Health Agency for Equality	British National Formulary
Blood Cancer UK	Care Quality Commission
Cancer Black Care	Department of Health - Northern Ireland
0 50	Healthcare Improvement Scotland
	Medicines and Healthcare products
<ul> <li>Helen Rollason Cancer Charity</li> <li>Independent Cancer Patients Voice</li> </ul>	Regulatory Agency
Kevin Kararwa Leukaemia Trust	<ul> <li>National Association of Primary Care</li> </ul>
	National Pharmacy Association
	NHS Confederation
	NHS Wales Joint Commissioning
	Committee
<ul><li>Lymphoma Action</li><li>Macmillan Cancer Support</li></ul>	Scottish Medicines Consortium
M	Welsh Government
<ul> <li>Maggie's Centres</li> <li>Marie Curie</li> </ul>	VVCISIT GOVCITITICITE
South Asian Health Foundation	Possible comparator companies
0 ' 1' 111 101 A11'	Celltrion Healthcare UK (rituximab)
<ul> <li>Specialised Healthcare Alliance</li> <li>Tenovus Cancer Care</li> </ul>	Dr Reddy's Laboratories (rituximab)
Teriovus Caricer Care	Pfizer (rituximab)
Healthcare professional groups	Roche (rituximab)
Association of Cancer Physicians	Sandoz (rituximab)
<ul> <li>British Geriatrics Society</li> </ul>	
British Institute of Radiology	Relevant research groups
British Oncology Pharmacy	Cochrane Haematology Group
Association	Genomics England
British Psychosocial Oncology Society	Institute of Cancer Research
<ul> <li>British Society for Haematology</li> </ul>	Leukaemia Busters
British Society of Interventional	Lymphoma Research Trust
Radiology	MRC Clinical Trials Unit
British Transplantation Society	National Institute for Health Research
Cancer Research UK	



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul> <li>NHS Blood and Transplant</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Oncology Nursing Society</li> </ul>	<ul> <li>Associated Public Health groups</li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>
<ul><li>Others</li><li>Department of Health and Social Care</li><li>NHS England</li></ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

#### Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.


#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).





### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.